Laser Modification of Dental Implant Abutment Surfaces

August 19, 2026 updated by: Alexandria University

Impact of Surface Modification of Abutments of Dental Implants by Laser on Soft Tissue Seal (A Randomized Controlled Clinical Trial)

Introduction: Tight soft tissue integration to the dental implants is essential to achieve a successful outcome of dental implants. Contamination by oral bacteria of the implant-mucosa interface can result in gingival recession, pocket formation, and bone resorption. There are many surface modification strategies to reinforce the soft tissue seal to dental implants. One of these strategies is laser technology. The aim of this study is to evaluate the effect of laser-induced roughness of titanium surfaces of final abutments on the connective tissue seal to the dental implant. Materials and Methods: Twenty-four pure titanium abutments of dental implants will be evaluated in this study. The abutments will be divided into 2 groups: group A will be treated with ND: YAG laser, and group B will not be treated with a laser as a control group. After 3 months, evaluation will be done by measuring peri-implant probing depth, modified gingival index, bleeding index, plaque index, and patient satisfaction.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Alexandria, Egypt
        • Outpatient Clinic of Periodontology and Oral medicine Department, Faculty of Dentistry, Alexandria University, Egypt

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • An informed consent will be signed from all the volunteers and they will be informed with all the steps, risk and benefits regarding the study.
  • Patients having osseointegrated implants ready to receive final abutment.

Exclusion Criteria:

  • The presence of chronic systemic disease.
  • Smoking of more than 10 cigarettes per day.
  • Bruxism habits.
  • Alcohol or drug abuse.
  • Poor oral hygiene.
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control Group
will include twelve abutments which will be left machined (as received from the manufacturer) to serve as controls.
Experimental: Study group
This will include twelve titanium abutments treated by ND: YAG laser with an output power 4 W, representing 80mJ for a period of 5 seconds (20).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change in peri-implant probing depth
Time Frame: up to 3 months
Desirable probing depths around dental implants are 2.5mm to 4mm. Peri-implantitis is often defined by the incidence of peri-implant probing depth ≥ 5 mm associated with bleeding on probing
up to 3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change in Modified gingival index (MGI)
Time Frame: up to 3 months

the scoring will be as follows: 0 = absence of inflammation,

  1. = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit,
  2. = mild inflammation; criteria as above but involving the entire marginal or papillary gingival unit,
  3. = moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit,
  4. = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration
up to 3 months
chaneg in Bleeding index (BI)
Time Frame: up to 3 months
The Bleeding Index (modified Index of Saxton), will be performed by using a dental probe. The probe will be engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure will be used while sweeping. The scoring system is as follows: 0 = no bleeding after 30 seconds, 1 = bleeding upon probing after 30 seconds, 2 = immediate bleeding observed
up to 3 months
change in Plaque index
Time Frame: up to 3 months
0 = no plaque. 1 = separate flecks of plaque at the cervical margin of the tooth. 2 = a thin continuous band of plaque (up to 1 mm) at the cervical margin of the tooth. 3 = a band of plaque wider than 1 mm but covering less than one-third of the crown of the tooth, 4= more than 1/3 but less than 2/3 of the tooth is covered with plaque , 5 indicated that more than 2/3 of the tooth surface is covered with plaque
up to 3 months
Patient satisfaction
Time Frame: up to 3 months
Patient satisfaction will be assessed using a visual analogue scale (VAS)
up to 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 15, 2025

Primary Completion (Actual)

December 25, 2025

Study Completion (Actual)

December 30, 2025

Study Registration Dates

First Submitted

August 19, 2026

First Submitted That Met QC Criteria

August 19, 2026

First Posted (Actual)

August 21, 2026

Study Record Updates

Last Update Posted (Actual)

August 21, 2026

Last Update Submitted That Met QC Criteria

August 19, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 1078-05/2025

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe